These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21663508)

  • 21. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive Transformation of Germinal Centers: Single-Center Experience of 33 Turkish Patients.
    Özkan MC; Özsan N; Hekimgil M; Saydam G; Töbü M
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S149-51. PubMed ID: 27133958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma.
    Kiil K; Bein J; Schuhmacher B; Thurner L; Schneider M; Hansmann ML; Hartmann S
    Virchows Arch; 2018 Dec; 473(6):759-764. PubMed ID: 30259184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.
    Zhao W; Gao Y; Bai B; Cai QC; Wang XX; Cai QQ; Huang HQ
    Expert Opin Drug Saf; 2015 Jan; 14(1):21-9. PubMed ID: 25412839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?
    Portlock CS; O'Connor OA; Straus DJ; Rosenzweig L; Dumitrescu O; Lin O; Maslak P
    Leuk Lymphoma; 2006 Jul; 47(7):1260-4. PubMed ID: 16923555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classical Hodgkin lymphoma occurring in clusters of nodal marginal zone B-lymphocytes in association with progressive transformation of germinal center. A case report.
    Kojima M; Nakamura S; Shimizu K; Tanaka H; Yamane Y; Sugihara S; Masawa N
    Pathol Res Pract; 2003; 199(8):547-50. PubMed ID: 14533939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.
    Haidenberger A; Fromm-Haidenberger S; de Vries A; Popper BA; Steurer M; Skvortsova I; Kantner J; Gunsilius E; Lukas P
    Strahlenther Onkol; 2011 May; 187(5):300-5. PubMed ID: 21544528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.
    Miyoshi H; Arakawa F; Sato K; Kimura Y; Kiyasu J; Takeuchi M; Yoshida M; Ichikawa A; Ishibashi Y; Nakamura Y; Nakashima S; Niino D; Sugita Y; Ohshima K
    Cancer Sci; 2012 Aug; 103(8):1567-73. PubMed ID: 22500644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
    Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
    J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
    Younes A; Romaguera J; Hagemeister F; McLaughlin P; Rodriguez MA; Fiumara P; Goy A; Jeha S; Manning JT; Jones D; Abruzzo LV; Medeiros LJ
    Cancer; 2003 Jul; 98(2):310-4. PubMed ID: 12872350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.